Progress in management of patent ductus arterious in preterm infants with gestational age of <28 weeks.
- Author:
Fang TIAN
1
;
Wen-Jing SHI
Author Information
1. Children's Hospital, Fudan University, Shanghai 201102, China tianfang20150130@126.com.
- Publication Type:Journal Article
- MeSH:
Ductus Arteriosus, Patent;
therapy;
Gestational Age;
Humans;
Infant, Newborn;
Infant, Premature
- From:
Chinese Journal of Contemporary Pediatrics
2015;17(10):1142-1147
- CountryChina
- Language:Chinese
-
Abstract:
Patent ductus arteriosus (PDA) is a common problem encountered in the early neonatal period, particularly in preterm infants. Optimal management of PDA in preterm infants remains controversial. Despite considerable historical and physiological data indicating a persistent PDA may be harmful, robust evidence of long-term benefits or harms from treatment is lacking. This has been equated to a lack of benefit but is also a reflection of the fact that many clinical trials were designed to assess the effects of short-term (2-8 days) rather than prolonged exposure to a PDA. No clinical trials have been designed to assess the effects of prolonged exposure of persistent PDA on morbidity and mortality of very premature infants. Significant changes in management of PDA, i.e., less treatment for PDA, have evolved in recent years. This paper reviews the current literature and evidence for treatment options and research progress of PDA in infants with gestational age of <28 weeks.
